|
ACADIA Pharmaceuticals Inc. (ACAD) DCF Valuation
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
ACADIA Pharmaceuticals Inc. (ACAD) Bundle
Designed for accuracy, our ACAD DCF Calculator enables you to evaluate ACADIA Pharmaceuticals Inc. (ACAD) valuation using real-world financial data and offers complete flexibility to modify all essential parameters for enhanced projections.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 339.1 | 441.8 | 484.1 | 517.2 | 726.4 | 884.7 | 1,077.5 | 1,312.3 | 1,598.2 | 1,946.5 |
| Revenue Growth, % | 0 | 30.28 | 9.6 | 6.83 | 40.45 | 21.79 | 21.79 | 21.79 | 21.79 | 21.79 |
| EBITDA | -243.8 | -286.6 | -167.1 | -221.6 | -67.8 | -395.4 | -481.6 | -586.5 | -714.3 | -869.9 |
| EBITDA, % | -71.9 | -64.87 | -34.51 | -42.84 | -9.34 | -44.69 | -44.69 | -44.69 | -44.69 | -44.69 |
| Depreciation | 2.8 | 2.9 | 3.3 | 2.0 | 5.6 | 5.9 | 7.2 | 8.7 | 10.6 | 12.9 |
| Depreciation, % | 0.81575 | 0.66372 | 0.6907 | 0.3917 | 0.76428 | 0.66523 | 0.66523 | 0.66523 | 0.66523 | 0.66523 |
| EBIT | -246.5 | -289.5 | -170.4 | -223.6 | -73.4 | -401.3 | -488.7 | -595.2 | -724.9 | -882.9 |
| EBIT, % | -72.71 | -65.54 | -35.2 | -43.23 | -10.1 | -45.36 | -45.36 | -45.36 | -45.36 | -45.36 |
| Total Cash | 697.4 | 632.0 | 520.7 | 416.8 | 438.9 | 780.3 | 950.4 | 1,157.4 | 1,409.6 | 1,716.8 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 37.9 | 50.3 | 65.3 | 63.1 | 102.4 | 110.3 | 134.3 | 163.6 | 199.2 | 242.7 |
| Account Receivables, % | 11.17 | 11.38 | 13.5 | 12.2 | 14.09 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 |
| Inventories | 6.3 | 9.7 | 7.9 | 6.6 | 35.8 | 21.1 | 25.7 | 31.2 | 38.0 | 46.3 |
| Inventories, % | 1.87 | 2.19 | 1.63 | 1.28 | 4.93 | 2.38 | 2.38 | 2.38 | 2.38 | 2.38 |
| Accounts Payable | 7.2 | 8.5 | 6.9 | 12.7 | 17.5 | 18.3 | 22.3 | 27.2 | 33.1 | 40.3 |
| Accounts Payable, % | 2.13 | 1.92 | 1.42 | 2.46 | 2.41 | 2.07 | 2.07 | 2.07 | 2.07 | 2.07 |
| Capital Expenditure | -1.1 | -7.6 | -1.1 | .0 | -40.1 | -13.8 | -16.8 | -20.5 | -24.9 | -30.3 |
| Capital Expenditure, % | -0.33296 | -1.72 | -0.23175 | 0 | -5.51 | -1.56 | -1.56 | -1.56 | -1.56 | -1.56 |
| Tax Rate, % | -20.08 | -20.08 | -20.08 | -20.08 | -20.08 | -20.08 | -20.08 | -20.08 | -20.08 | -20.08 |
| EBITAT | -247.5 | -290.1 | -170.8 | -226.2 | -88.1 | -401.3 | -488.7 | -595.2 | -724.9 | -882.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -282.8 | -309.3 | -183.5 | -214.8 | -186.3 | -401.6 | -523.0 | -636.9 | -775.7 | -944.8 |
| WACC, % | 6.2 | 6.2 | 6.2 | 6.2 | 6.2 | 6.2 | 6.2 | 6.2 | 6.2 | 6.2 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -2,682.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -964 | |||||||||
| Terminal Value | -22,929 | |||||||||
| Present Terminal Value | -16,971 | |||||||||
| Enterprise Value | -19,653 | |||||||||
| Net Debt | -131 | |||||||||
| Equity Value | -19,522 | |||||||||
| Diluted Shares Outstanding, MM | 164 | |||||||||
| Equity Value Per Share | -119.17 |
What You Will Get
- Real ACAD Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on ACADIA Pharmaceuticals' fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.
Key Features
- Customizable Financial Inputs: Adjust essential metrics such as revenue projections, R&D expenses, and operating margins.
- Instant DCF Valuation: Quickly determines intrinsic value, NPV, and additional financial metrics.
- High-Precision Accuracy: Incorporates ACADIA’s actual financial data for credible valuation results.
- Effortless Scenario Testing: Evaluate various assumptions and analyze results with ease.
- Efficiency Booster: Streamline the valuation process without the hassle of constructing intricate models from the ground up.
How It Works
- Download the Template: Gain immediate access to the Excel-based ACAD DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other key metrics.
- Instant Calculations: The model automatically recalculates ACAD's intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential changes in valuation.
- Analyze and Decide: Utilize the results to inform your investment or financial strategies.
Why Choose ACADIA Pharmaceuticals Inc. (ACAD) Calculator?
- Comprehensive Tool: Incorporates DCF, WACC, and financial ratio analyses tailored for ACAD.
- Customizable Inputs: Modify yellow-highlighted cells to explore different financial scenarios for ACAD.
- Detailed Insights: Automatically computes ACAD’s intrinsic value and Net Present Value.
- Preloaded Data: Historical and projected data provide reliable starting points for analysis.
- Professional Quality: Perfect for financial analysts, investors, and business consultants focusing on ACAD.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling ACADIA Pharmaceuticals Inc. (ACAD) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models for ACADIA Pharmaceuticals Inc. (ACAD).
- Consultants: Deliver professional valuation insights on ACADIA Pharmaceuticals Inc. (ACAD) to clients quickly and accurately.
- Business Owners: Understand how biopharmaceutical companies like ACADIA Pharmaceuticals Inc. (ACAD) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to ACADIA Pharmaceuticals Inc. (ACAD).
What the Template Contains
- Pre-Filled DCF Model: ACADIA Pharmaceuticals’ financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate ACADIA’s profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.